{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:14:47Z","timestamp":1793394887159,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr Metab (Lond)"],"DOI":"10.1186\/s12986-025-00927-y","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T08:31:17Z","timestamp":1747038677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical characteristics of lean and non-lean non-alcoholic fatty liver disease: a cross-sectional study"],"prefix":"10.1186","volume":"22","author":[{"given":"Mengyan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"927_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1146\/annurev-med-042220-020407","volume":"73","author":"Y Saiman","year":"2022","unstructured":"Saiman Y, Duarte-Rojo A, Rinella ME. Fatty liver disease: diagnosis and stratification. Annu Rev Med. 2022;73:529\u201344.","journal-title":"Annu Rev Med"},{"key":"927_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335.","journal-title":"Hepatology"},{"key":"927_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"927_CR4","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","volume":"163","author":"MT Long","year":"2022","unstructured":"Long MT, Noureddin M, Lim JK. AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. Gastroenterology. 2022;163:764-774.e1.","journal-title":"Gastroenterology"},{"key":"927_CR5","doi-asserted-by":"crossref","unstructured":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157\u201363.","DOI":"10.1016\/S0140-6736(03)15268-3"},{"key":"927_CR6","doi-asserted-by":"crossref","unstructured":"New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67:862\u201373.","DOI":"10.1016\/j.jhep.2017.06.003"},{"key":"927_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.metabol.2018.09.005","volume":"92","author":"YC Chooi","year":"2019","unstructured":"Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6\u201310.","journal-title":"Metabolism"},{"key":"927_CR8","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69:2672.","journal-title":"Hepatology"},{"key":"927_CR9","doi-asserted-by":"crossref","unstructured":"Clinical and patient-reported outcomes from patients with nonalcoholic fatty liver disease across the world: data from the global non-alcoholic steatohepatitis (NASH)\/ non-alcoholic fatty liver disease (NAFLD) registry. Clin Gastroenterol Hepatol. 2022;20:2296\u20132306.e6.","DOI":"10.1016\/j.cgh.2021.11.004"},{"key":"927_CR10","doi-asserted-by":"crossref","unstructured":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202\u20139.","DOI":"10.1016\/j.jhep.2020.07.045"},{"key":"927_CR11","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739\u201352.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"927_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep4.1124","volume":"2","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, Hammar U, St\u00e5l P, Hultcrantz R, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. Hepatol Commun. 2017;2:48\u201357.","journal-title":"Hepatol Commun"},{"key":"927_CR13","unstructured":"The most recent and in-depth meta-analytic assessment of the global epidemiology of non-alcoholic fatty liver disease (NAFLD) | Semantic Scholar [Internet]. [cited 2024 Aug 27]. Available from: https:\/\/www.semanticscholar.org\/paper\/The-most-recent-and-in-depth-meta-analytic-of-the-Younossi-Golabi\/1ef0c2ee13614c6d7cf33f3afb6ccde74d927f0d"},{"key":"927_CR14","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. International consensus panel: MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1.","journal-title":"Gastroenterology"},{"key":"927_CR15","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","volume":"29","author":"ME Rinella","year":"2024","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29:101133.","journal-title":"Ann Hepatol"},{"key":"927_CR16","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","volume":"80","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80:e76\u20137.","journal-title":"J Hepatol"},{"key":"927_CR17","doi-asserted-by":"publisher","first-page":"102581","DOI":"10.1016\/j.dsx.2022.102581","volume":"16","author":"DL Tahapary","year":"2022","unstructured":"Tahapary DL, Pratisthita LB, Fitri NA, Marcella C, Wafa S, Kurniawan F, et al. Challenges in the diagnosis of insulin resistance: focusing on the role of HOMA-IR and Tryglyceride\/glucose index. Diabetes Metab Syndr. 2022;16:102581.","journal-title":"Diabetes Metab Syndr"},{"key":"927_CR18","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1111\/jdi.13536","volume":"12","author":"Z Cai","year":"2021","unstructured":"Cai Z, Chen Z, Fang W, Li W, Huang Z, Wang X, et al. Triglyceride to high-density lipoprotein cholesterol ratio variability and incident diabetes: a 7-year prospective study in a Chinese population. J Diabetes Investig. 2021;12:1864\u201371.","journal-title":"J Diabetes Investig"},{"key":"927_CR19","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2337\/dc10-2234","volume":"34","author":"C Giannini","year":"2011","unstructured":"Giannini C, Santoro N, Caprio S, Kim G, Lartaud D, Shaw M, et al. The triglyceride-to-HDL cholesterol ratio. Diabetes Care. 2011;34:1869\u201374.","journal-title":"Diabetes Care"},{"key":"927_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12933-024-02308-w","volume":"23","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Liu Q, Zheng M, Zuo Z, Zhang G, Shi R, et al. Comparative study on the predictive value of TG\/HDL-C, TyG and TyG-BMI indices for 5-year mortality in critically ill patients with chronic heart failure: a retrospective study. Cardiovasc Diabetol. 2024;23:213.","journal-title":"Cardiovasc Diabetol"},{"key":"927_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","volume":"17","author":"MS Siddiqui","year":"2019","unstructured":"Siddiqui MS, Vuppalanchi R, Van Natta ML, Hallinan E, Kowdley KV, Abdelmalek M, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17:156-163.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"927_CR22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/hep.23312","volume":"51","author":"VW-S Wong","year":"2010","unstructured":"Wong VW-S, Vergniol J, Wong GL-H, Foucher J, Chan HL-Y, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454\u201362.","journal-title":"Hepatology"},{"key":"927_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3350\/cmh.2019.0065","volume":"26","author":"SH Park","year":"2019","unstructured":"Park SH, Plank LD, Suk KT, Park YE, Lee J, Choi JH, et al. Trends in the prevalence of chronic liver disease in the Korean adult population, 1998\u20132017. Clin Mol Hepatol. 2019;26:209.","journal-title":"Clin Mol Hepatol"},{"key":"927_CR24","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"927_CR25","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47-64.","journal-title":"J Hepatol"},{"key":"927_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2018.0037","volume":"25","author":"J-J Yoo","year":"2018","unstructured":"Yoo J-J, Kim W, Kim MY, Jun DW, Kim SG, Yeon J-E, et al. Recent research trends and updates on nonalcoholic fatty liver disease. Clin Mol Hepatol. 2018;25:1.","journal-title":"Clin Mol Hepatol"},{"key":"927_CR27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/liv.15078","volume":"42","author":"H Lin","year":"2022","unstructured":"Lin H, Wong GL-H, Whatling C, Chan AW-H, Leung HH-W, Tse C-H, et al. Association of genetic variations with NAFLD in lean individuals. Liver Int. 2022;42:149\u201360.","journal-title":"Liver Int"},{"key":"927_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16164","author":"Y Seko","year":"2025","unstructured":"Seko Y, Lin H, Wong VW-S, Okanoue T. Impact of in lean individuals and in cryptogenic steatotic liver disease. Liver Int. 2025. https:\/\/doi.org\/10.1111\/liv.16164.","journal-title":"Liver Int"},{"key":"927_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13293-022-00416-4","volume":"13","author":"C Strack","year":"2022","unstructured":"Strack C, Behrens G, Sag S, Mohr M, Zeller J, Lahmann C, et al. Gender differences in cardiometabolic health and disease in a cross-sectional observational obesity study. Biol Sex Differ. 2022;13:8.","journal-title":"Biol Sex Differ"},{"key":"927_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1467-789X.2008.00529.x","volume":"10","author":"JC Lovejoy","year":"2009","unstructured":"Lovejoy JC, Sainsbury A. Stock conference 2008 Working group: sex differences in obesity and the regulation of energy homeostasis. Obes Rev. 2009;10:154\u201367.","journal-title":"Obes Rev"},{"key":"927_CR31","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/hep4.1419","volume":"3","author":"JM Paik","year":"2019","unstructured":"Paik JM, Henry L, Avila LD, Younossi E, Racila A, Younossi ZM. Mortality related to nonalcoholic fatty liver disease is increasing in the United States. Hepatol Commun. 2019;3:1459.","journal-title":"Hepatol Commun"},{"key":"927_CR32","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/hep.26761","volume":"59","author":"JD Yang","year":"2014","unstructured":"Yang JD, Abdelmalek MF, Pang H, Guy CD, Smith AD, Diehl AM, et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology. 2014;59:1406.","journal-title":"Hepatology"},{"key":"927_CR33","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/ajg.2015.235","volume":"110","author":"JL Wei","year":"2015","unstructured":"Wei JL, Leung JC-F, Loong TC-W, Wong GL-H, Yeung DK-W, Chan RS-M, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol. 2015;110:1306\u201314.","journal-title":"Am J Gastroenterol"},{"key":"927_CR34","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-23-0245","author":"M Gado","year":"2024","unstructured":"Gado M, Tsaousidou E, Bornstein SR, Perakakis N. Sex-based differences in insulin resistance. J Endocrinol. 2024. https:\/\/doi.org\/10.1530\/JOE-23-0245.","journal-title":"J Endocrinol"},{"key":"927_CR35","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.ajpath.2021.05.011","volume":"191","author":"M De Paoli","year":"2021","unstructured":"De Paoli M, Zakharia A, Werstuck GH. The role of estrogen in insulin resistance: a review of clinical and preclinical data. Am J Pathol. 2021;191:1490\u20138.","journal-title":"Am J Pathol"},{"key":"927_CR36","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","volume":"15","author":"QM Anstee","year":"2018","unstructured":"Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018;15:425\u201339.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"927_CR37","first-page":"691","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691\u2013702.","journal-title":"Gut"},{"key":"927_CR38","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s10620-016-4040-6","volume":"61","author":"A Mantovani","year":"2016","unstructured":"Mantovani A, Ballestri S, Lonardo A, Targher G. Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease. Dig Dis Sci. 2016;61:1246\u201367.","journal-title":"Dig Dis Sci"},{"key":"927_CR39","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/hep4.1155","volume":"2","author":"Y-Y Zhou","year":"2018","unstructured":"Zhou Y-Y, Zhou X-D, Wu S-J, Fan D-H, Van Poucke S, Chen Y-P, et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis. Hepatol Commun. 2018;2:376.","journal-title":"Hepatol Commun"},{"key":"927_CR40","first-page":"533","volume":"73","author":"H-H Lee","year":"2024","unstructured":"Lee H-H, Lee HA, Kim E-J, Kim HY, Kim HC, Ahn SH, et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2024;73:533\u201340.","journal-title":"Gut"},{"key":"927_CR41","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0002-9343(99)00271-5","volume":"107","author":"G Marchesini","year":"1999","unstructured":"Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450\u20135.","journal-title":"Am J Med"},{"key":"927_CR42","doi-asserted-by":"publisher","first-page":"eaay8798","DOI":"10.1126\/scitranslmed.aay8798","volume":"12","author":"S Alsamman","year":"2020","unstructured":"Alsamman S, Christenson SA, Yu A, Ayad NME, Mooring MS, Segal JM, et al. Targeting acid ceramidase inhibits YAP\/TAZ signaling to reduce fibrosis in mice. Sci Transl Med. 2020;12:eaay8798.","journal-title":"Sci Transl Med"},{"key":"927_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature21363","volume":"542","author":"GS Hotamisligil","year":"2017","unstructured":"Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542:177\u201385.","journal-title":"Nature"},{"key":"927_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cmet.2020.11.010","volume":"33","author":"SR Sharpton","year":"2021","unstructured":"Sharpton SR, Schnabl B, Knight R, Loomba R. Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease. Cell Metab. 2021;33:21\u201332.","journal-title":"Cell Metab"},{"key":"927_CR45","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.cmet.2023.06.011","volume":"35","author":"S Verma","year":"2023","unstructured":"Verma S, Mazer CD, Connelly KA. Inflammation and cholesterol at the crossroads of vascular risk. Cell Metab. 2023;35:1095\u20138.","journal-title":"Cell Metab"},{"key":"927_CR46","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/CM9.0000000000002753","volume":"137","author":"M Yuan","year":"2024","unstructured":"Yuan M, He J, Hu X, Yao L, Chen P, Wang Z, et al. Hypertension and NAFLD risk: Insights from the NHANES 2017\u20132018 and Mendelian randomization analyses. Chin Med J (Engl). 2024;137:457\u201364.","journal-title":"Chin Med J (Engl)"},{"key":"927_CR47","doi-asserted-by":"publisher","first-page":"100892","DOI":"10.1016\/j.aohep.2022.100892","volume":"28","author":"J Liu","year":"2023","unstructured":"Liu J, Lv H, Wang J, Zhu Q, Chen G, Jiang Y, et al. Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease. Ann Hepatol. 2023;28:100892.","journal-title":"Ann Hepatol"},{"key":"927_CR48","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/liv.14044","volume":"39","author":"A Mantovani","year":"2019","unstructured":"Mantovani A, Dauriz M, Sandri D, Bonapace S, Zoppini G, Tilg H, et al. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. Liver Int. 2019;39:758\u201369.","journal-title":"Liver Int"},{"key":"927_CR49","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","volume":"365","author":"RH Eckel","year":"2005","unstructured":"Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. The Lancet. 2005;365:1415\u201328.","journal-title":"The Lancet"},{"key":"927_CR50","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","volume":"10","author":"N Stefan","year":"2022","unstructured":"Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10:284\u201396.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"927_CR51","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","volume":"18","author":"G Targher","year":"2021","unstructured":"Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus: mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18:599\u2013612.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"927_CR52","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc17-1902","volume":"41","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care. 2018;41:372\u201382.","journal-title":"Diabetes Care"},{"key":"927_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12916-017-0806-8","volume":"15","author":"BA Neuschwander-Tetri","year":"2017","unstructured":"Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15:45.","journal-title":"BMC Med"},{"key":"927_CR54","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","volume":"2","author":"H Yki-J\u00e4rvinen","year":"2014","unstructured":"Yki-J\u00e4rvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901\u201310.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"927_CR55","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/hep4.1618","volume":"5","author":"J Vieira Barbosa","year":"2020","unstructured":"Vieira Barbosa J, Lai M. Nonalcoholic fatty liver disease screening in type 2 diabetes mellitus patients in the primary care setting. Hepatol Commun. 2020;5:158\u201367.","journal-title":"Hepatol Commun"},{"key":"927_CR56","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jhep.2008.11.021","volume":"50","author":"Y Li","year":"2009","unstructured":"Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol. 2009;50:1029\u201334.","journal-title":"J Hepatol"},{"key":"927_CR57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ejim.2022.04.022","volume":"103","author":"S Copur","year":"2022","unstructured":"Copur S, Demiray A, Kanbay M. Uric acid in metabolic syndrome: Does uric acid have a definitive role? Eur J Intern Med. 2022;103:4\u201312.","journal-title":"Eur J Intern Med"},{"key":"927_CR58","doi-asserted-by":"publisher","first-page":"j2376","DOI":"10.1136\/bmj.j2376","volume":"357","author":"X Li","year":"2017","unstructured":"Li X, Meng X, Timofeeva M, Tzoulaki I, Tsilidis KK, Ioannidis JP, et al. Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. BMJ. 2017;357:j2376.","journal-title":"BMJ"},{"key":"927_CR59","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/cen.14673","volume":"96","author":"L Fern\u00e1ndez-Chirino","year":"2022","unstructured":"Fern\u00e1ndez-Chirino L, Antonio-Villa NE, Ferm\u00edn-Mart\u00ednez CA, M\u00e1rquez-Salinas A, Guerra EC, Vargas-V\u00e1zquez A, et al. Elevated serum uric acid is a facilitating mechanism for insulin resistance mediated accumulation of visceral adipose tissue. Clin Endocrinol. 2022;96:707\u201318.","journal-title":"Clin Endocrinol"},{"key":"927_CR60","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.3346\/jkms.2019.34.e7","volume":"34","author":"HU Moon","year":"2019","unstructured":"Moon HU, Ha KH, Han SJ, Kim HJ, Kim DJ. The association of adiponectin and visceral fat with insulin resistance and \u03b2-cell dysfunction. J Korean Med Sci. 2019;34:e7.","journal-title":"J Korean Med Sci"},{"key":"927_CR61","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/BOR.0b013e32835d951e","volume":"25","author":"C Li","year":"2013","unstructured":"Li C, Hsieh M-C, Chang S-J. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25:210.","journal-title":"Curr Opin Rheumatol"},{"key":"927_CR62","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.2337\/db10-0916","volume":"60","author":"W Baldwin","year":"2011","unstructured":"Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60:1258.","journal-title":"Diabetes"},{"key":"927_CR63","doi-asserted-by":"publisher","first-page":"101231","DOI":"10.1016\/j.mam.2023.101231","volume":"95","author":"M Parola","year":"2024","unstructured":"Parola M, Pinzani M. Liver fibrosis in NAFLD\/NASH: from pathophysiology towards diagnostic and therapeutic strategies. Mol Aspects Med. 2024;95:101231.","journal-title":"Mol Aspects Med"},{"key":"927_CR64","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/apt.14112","volume":"46","author":"S Sookoian","year":"2017","unstructured":"Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017;46:85\u201395.","journal-title":"Aliment Pharmacol Ther"},{"key":"927_CR65","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/hep.28697","volume":"65","author":"JC-F Leung","year":"2017","unstructured":"Leung JC-F, Loong TC-W, Wei JL, Wong GL-H, Chan AW-H, Choi PC-L, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2017;65:54\u201364.","journal-title":"Hepatology"},{"key":"927_CR66","doi-asserted-by":"publisher","first-page":"14832","DOI":"10.1096\/fj.202001495R","volume":"34","author":"MS Muyyarikkandy","year":"2020","unstructured":"Muyyarikkandy MS, McLeod M, Maguire M, Mahar R, Kattapuram N, Zhang C, et al. Branched chain amino acids and carbohydrate restriction exacerbate ketogenesis and hepatic mitochondrial oxidative dysfunction during NAFLD. FASEB J. 2020;34:14832\u201349.","journal-title":"FASEB J"},{"key":"927_CR67","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI134165","volume":"130","author":"GI Smith","year":"2020","unstructured":"Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2020;130:1453\u201360.","journal-title":"J Clin Invest"},{"key":"927_CR68","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4158\/EP-2019-0342","volume":"26","author":"H Bian","year":"2020","unstructured":"Bian H, Zhu X, Xia M, Yan H, Chang X, Hu X, et al. Impact of type 2 diabetes on nonalcoholic steatohepatitis and advanced fibrosis in patients with nonalcoholic fatty liver disease. Endocr Pract. 2020;26:444\u201353.","journal-title":"Endocr Pract"},{"key":"927_CR69","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jhep.2023.11.015","volume":"80","author":"X Fan","year":"2024","unstructured":"Fan X, Shi Y, Han J, Song Y, Zhao J. Beyond body weight: Diversified presentation of MASLD in lean, overweight, and obese participants. J Hepatol. 2024;80:e147\u201350.","journal-title":"J Hepatol"},{"key":"927_CR70","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3109\/09537100903391023","volume":"21","author":"H Ozhan","year":"2010","unstructured":"Ozhan H, Aydin M, Yazici M, Yazgan O, Basar C, Gungor A, et al. Mean platelet volume in patients with non-alcoholic fatty liver disease. Platelets. 2010;21:29\u201332.","journal-title":"Platelets"},{"key":"927_CR71","doi-asserted-by":"publisher","first-page":"5753","DOI":"10.3748\/wjg.v27.i34.5753","volume":"27","author":"Y-L Wu","year":"2021","unstructured":"Wu Y-L, Kumar R, Wang M-F, Singh M, Huang J-F, Zhu Y-Y, et al. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World J Gastroenterol. 2021;27:5753\u201363.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"927_CR72","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","volume":"161","author":"F Kanwal","year":"2021","unstructured":"Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wong VWS, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161(5):1657\u201369. https:\/\/doi.org\/10.1053\/j.gastro.2021.07.049.","journal-title":"Gastroenterology"},{"issue":"7","key":"927_CR73","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.cgh.2024.02.008","volume":"22","author":"M Chang","year":"2024","unstructured":"Chang M, Chang D, Kodali S, Harrison SA, Ghobrial M, Alkhouri N, Noureddin M. Degree of discordance between FIB-4 and transient elastography: an application of current guidelines on general population cohort. Clin Gastroenterol Hepatol. 2024;22(7):1453-1461.e2. https:\/\/doi.org\/10.1016\/j.cgh.2024.02.008.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"927_CR74","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1007\/s10620-023-08085-y","volume":"68","author":"U Arora","year":"2023","unstructured":"Arora U, Goyal RM, Teh KKJ, Pei Y, Goh GBB, Lin S, et al. Poor performance of non-invasive tests for advanced fibrosis in nonalcoholic fatty liver disease: a multicentric asian study. Dig Dis Sci. 2023;68:4485\u201398.","journal-title":"Dig Dis Sci"}],"container-title":["Nutrition &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12986-025-00927-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12986-025-00927-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12986-025-00927-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T09:10:30Z","timestamp":1747041030000},"score":1,"resource":{"primary":{"URL":"https:\/\/nutritionandmetabolism.biomedcentral.com\/articles\/10.1186\/s12986-025-00927-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["927"],"URL":"https:\/\/doi.org\/10.1186\/s12986-025-00927-y","relation":{},"ISSN":["1743-7075"],"issn-type":[{"value":"1743-7075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"4 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Wuhan Union Hospital Ethics Committee and the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (IORG No: ([2022]0422)) and performed in accordance with the Declaration of Helsinki. The data are anonymous, and the requirement for informed consent was therefore waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}